+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06588010

Randomized Double-Blind Study Evaluating OM-89 Versus Placebo to Reduce Antibiotic Use for Urinary Tract Infections in Patients with Neurogenic Bladder

Led by Centre Hospitalier Universitaire Dijon · Updated on 2026-09-08

110

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Recurrent urinary tract infections UTIs are a significant problem for patients with neurogenic bladder who use clean intermittent catheterization CIC. These infections cause frequent illness and are a leading cause of death and healthcare use in this group. Multidrug-resistant bacteria are common due to repeated antibiotic use and hospital stays. Preventing UTIs with non-antibiotic methods is important to reduce antibiotic exposure and resistance, but few effective options exist, especially for high-risk patients. This trial evaluates the use of OM-89, an immunoactive bacterial lysate derived from Escherichia coli, as a preventive treatment for recurrent UTIs in patients with neurogenic bladder. Participants will receive either OM-89 capsules or placebo in two phases first, one capsule daily for 90 days followed by 90 days without treatment, then one capsule daily for 10 days each month for three months. In the placebo group, participants will receive placebo during the first phase followed by OM-89 in the second phase following the same schedule. Participants will be monitored for one year to assess the number of antibiotic treatment episodes for UTIs. They will provide daily diaries and undergo clinical evaluations to track infections and antibiotic use. The study measures the effectiveness of OM-89 in reducing antibiotic consumption and its impact on bacterial resistance and urinary and digestive microbiota. This trial aims to improve prevention strategies in this vulnerable population and may inform care for others with recurrent UTIs.

CONDITIONS

Brief Title

Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder

Research Team

L

Lionel PIROTH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here